Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?
11:36am, Thursday, 02'nd Oct 2025
Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average
10:31am, Thursday, 02'nd Oct 2025
From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 50-day moving average, and this suggests a short
2 Beaten-Down Stocks to Buy and Hold for a Decade
07:30am, Tuesday, 30'th Sep 2025
Over the past couple of years, Moderna (MRNA 3.39%) and Regeneron Pharmaceuticals (REGN -0.62%) have encountered company-specific headwinds that have sunk their stock prices. The former is down by 75%
3 Of My Favorite Biotech Stocks Under $10
01:15pm, Monday, 29'th Sep 2025
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
12:37pm, Thursday, 25'th Sep 2025
Moderna, Inc. (NASDAQ:MRNA ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 25, 2025 10:30 AM EDT Company Participants Rose Loughlin - Executive Vice Pre
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
07:01pm, Wednesday, 24'th Sep 2025
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population The facility marks a
Moderna: Maintaining Sell Despite Consolidation - And Why MRNY Won't Help Either
04:59pm, Wednesday, 24'th Sep 2025
Moderna (MRNA) remains a Sell due to weak fundamentals, ongoing cash burn, and lack of meaningful pipeline breakthroughs or financial turnaround. MRNY, the YieldMax MRNA Option Income Strategy ETF, fa
Moderna says updated next-generation COVID shot shows strong immune response in patients
07:08am, Tuesday, 23'rd Sep 2025
Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
07:00am, Tuesday, 23'rd Sep 2025
Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna's COVID-19 vaccines for the
CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids
04:24pm, Friday, 19'th Sep 2025
Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines.
Mizuho's Jared Holz: There's not much value left in vaccine stocks
11:40am, Friday, 19'th Sep 2025
Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and
The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut
01:49pm, Thursday, 18'th Sep 2025
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna and Novavax.
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
11:05am, Wednesday, 17'th Sep 2025
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
06:00am, Tuesday, 16'th Sep 2025
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
10:01am, Monday, 15'th Sep 2025
MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.
